ACNP - Italian Periodicals Catalogue

AAAAAA

ITA
ENG

Results: 1-10 |

Results: 10

Authors: SPIGSET O GRANBERG K HAGG S SODERSTROM E DAHLQVIST R

Citation: O. Spigset et al., NONLINEAR FLUVOXAMINE DISPOSITION, British journal of clinical pharmacology, 45(3), 1998, pp. 257-263

PREVALENCE OF DIABETES AND IMPAIRED GLUCOSE-TOLERANCE IN PATIENTS TREATED WITH CLOZAPINE COMPARED WITH PATIENTS TREATED WITH CONVENTIONAL DEPOT NEUROLEPTIC MEDICATIONS

Authors: HAGG S JOELSSON L MJORNDAL T SPIGSET O OJA G DAHLQVIST R

Citation: S. Hagg et al., PREVALENCE OF DIABETES AND IMPAIRED GLUCOSE-TOLERANCE IN PATIENTS TREATED WITH CLOZAPINE COMPARED WITH PATIENTS TREATED WITH CONVENTIONAL DEPOT NEUROLEPTIC MEDICATIONS, The Journal of clinical psychiatry, 59(6), 1998, pp. 294-299

DENGLER,HANS,J - IN-MEMORIAM

Authors: SJOQVIST F EICHELBAUM M DAHLQVIST R

Citation: F. Sjoqvist et al., DENGLER,HANS,J - IN-MEMORIAM, European Journal of Clinical Pharmacology, 54(7), 1998, pp. 495-495

URINARY-EXCRETION OF CODEINE, ETHYLMORPHINE, AND THEIR METABOLITES - RELATION TO THE CYP2D6 ACTIVITY

Authors: HEDENMALM K SUNDGREN M GRANBERG K SPIGSET O DAHLQVIST R

Citation: K. Hedenmalm et al., URINARY-EXCRETION OF CODEINE, ETHYLMORPHINE, AND THEIR METABOLITES - RELATION TO THE CYP2D6 ACTIVITY, Therapeutic drug monitoring, 19(6), 1997, pp. 643-649

RELATIONSHIP BETWEEN FLUVOXAMINE PHARMACOKINETICS AND CYP2D6 CYP2C19 PHENOTYPE POLYMORPHISMS/

Authors: SPIGSET O GRANBERG K HAGG S NORSTROM A DAHLQVIST R

Citation: O. Spigset et al., RELATIONSHIP BETWEEN FLUVOXAMINE PHARMACOKINETICS AND CYP2D6 CYP2C19 PHENOTYPE POLYMORPHISMS/, European Journal of Clinical Pharmacology, 52(2), 1997, pp. 129-133

SEIZURES AND MYOCLONUS ASSOCIATED WITH ANTIDEPRESSANT TREATMENT - ASSESSMENT OF POTENTIAL RISK-FACTORS, INCLUDING CYP2D6 AND CYP2C19 POLYMORPHISMS, AND TREATMENT WITH CYP2D6 INHIBITORS

Authors: SPIGSET O HEDENMALM K DAHL ML WIHOLM BE DAHLQVIST R

Citation: O. Spigset et al., SEIZURES AND MYOCLONUS ASSOCIATED WITH ANTIDEPRESSANT TREATMENT - ASSESSMENT OF POTENTIAL RISK-FACTORS, INCLUDING CYP2D6 AND CYP2C19 POLYMORPHISMS, AND TREATMENT WITH CYP2D6 INHIBITORS, Acta psychiatrica Scandinavica, 96(5), 1997, pp. 379-384

EDITORIAL

Authors: DAHLQVIST R LANGE R

Citation: R. Dahlqvist et R. Lange, EDITORIAL, European Journal of Clinical Pharmacology, 51(3-4), 1996, pp. 197-197

EFFECT OF CIGARETTE SMOLTING ON FLUVOXAMINE PHARMACOKINETICS IN HUMANS

Authors: SPIGSET O CARLEBORG L HEDENMALM I DAHLQVIST R

Citation: O. Spigset et al., EFFECT OF CIGARETTE SMOLTING ON FLUVOXAMINE PHARMACOKINETICS IN HUMANS, Clinical pharmacology and therapeutics, 58(4), 1995, pp. 399-403

DMSA ADMINISTRATION TO PATIENTS WITH ALLEGED MERCURY-POISONING FROM DENTAL AMALGAMS - A PLACEBO-CONTROLLED STUDY

Authors: ENGLUND GS DAHLQVIST R LINDELOF B SODERMAN E JONZON B VESTERBERG O LARSSON KS

Citation: Gs. Englund et al., DMSA ADMINISTRATION TO PATIENTS WITH ALLEGED MERCURY-POISONING FROM DENTAL AMALGAMS - A PLACEBO-CONTROLLED STUDY, Journal of dental research, 73(3), 1994, pp. 620-628

INDOMETHACIN BUT NOT METOPROLOL REDUCES EXERCISE-INDUCED ALBUMIN EXCRETION RATE IN TYPE-1 DIABETIC-PATIENTS WITH MICROALBUMINURIA

Authors: RUDBERG S SATTERSTROM G DAHLQVIST R DAHLQUIST G

Citation: S. Rudberg et al., INDOMETHACIN BUT NOT METOPROLOL REDUCES EXERCISE-INDUCED ALBUMIN EXCRETION RATE IN TYPE-1 DIABETIC-PATIENTS WITH MICROALBUMINURIA, Diabetic medicine, 10(5), 1993, pp. 460-464

Risultati: 1-10 |